Histone deacetylase (HDAC) inhibitors are expected to be effective for refractory cancer because their mechanism of action differs from that of conventional antineoplastic agents. In this study, we ...

VS-7375, a potential best-in-class oral KRAS G12D (ON/OFF) inhibitor more potent than other KRAS G12D inhibitors in preclinical models VS-7375, when combined with cetuximab, demonstrated strong tumor ...

The effective targeting of RAS-mutant acute myeloid leukemia (AML) still remains a challenge; RAS mutations are tied to relapse to targeted therapy, such as resistance to FLT3 inhibitors due to the ...

As many as 50 percent of human cancer cases -- across a wide variety of tissues -- involve defects in a common cellular growth signaling pathway. These defects have so far defied most attempts to ...

Erasca, Inc. presents promising preclinical data on ERAS-0015 and ERAS-4001 targeting RAS/MAPK pathway cancers at AACR meeting. Erasca, Inc. presented new preclinical data at the American Association ...

Erasca, Inc. focuses on developing novel targeted therapies for solid tumors, particularly through the RAS/MAP kinase pathway, with a promising yet early-stage pipeline. The company’s lead program, ...

Ras mutations occur as an early event in many human tumours of epithelial origin, including thyroid. Using primary human thyroid epithelial cells to model tumour initiation by Ras, we have shown ...

Pancreatic ductal adenocarcinoma (PDAC) is characterized clinically by poor survival and mechanistically by KRAS- and autophagy-dependent growth. We and others previously demonstrated that inhibition ...

SOUTH SAN FRANCISCO - BridgeBio Oncology Therapeutics (NASDAQ:BBOT) announced Wednesday preliminary safety and efficacy data from three clinical-stage programs targeting RAS-pathway malignancies. The ...

Mitogen-activated protein kinase (MAPK) networks are essential for the transmission of extracellular signals into appropriate intracellular responses. Prototypical MAPK activation implements a ...